Locations:
Search IconSearch
September 15, 2021/Cancer

What Is the Role of Neoadjuvant Chemotherapy in Bladder Cancer With Variant Histology?

New findings could shape the treatment paradigm for a select group of bladder cancer patients

Plasmacytoid variant of urothelial carcinoma

Findings from a new Cleveland Clinic-led study help clarify the role of neoadjuvant chemotherapy in the management of bladder cancer with variant histology. Researchers presented these data at the 2021 American Urological Association meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The prognosis for variant histology is generally worse than that of pure urothelial carcinoma. The treatment paradigm for the latter includes neoadjuvant chemotherapy with cisplatin followed by radical cystectomy. Treatment for non-muscle invasive bladder cancer with variant histology favors an aggressive therapeutic approach, progressing to radical cystectomy as a first-line therapy and bypassing neoadjuvant treatment altogether.

For patients with muscle-invasive bladder cancer with variant histology (with the exception of small cell carcinoma), the use of neoadjuvant treatment is unclear.

Rebecca Campbell, MD, a resident in Cleveland Clinic’s Glickman Urological & Kidney Institute and first author of the study, says this ambiguity led to a multi-institutional collaboration with colleagues at Mayo Clinic that helped jumpstart this investigation and others.

“These histologies are very rare and all previous literature comes from small single-institution series.”

Multi-institutional collaboration to address a gap in the literature

Together the teams partnered to create a larger database of patients with variant histology undergoing radical cystectomy than has previously been reported. They decided which histologies to include – urothelial, sarcomatoid, small cell carcinoma, nested, micropapillary and plasmacytoid – and determined pathologic downstaging after neoadjuvant chemotherapy would be a clinically meaningful endpoint.

“Downstaging occurred if the pathologic tumor stage at the time of radical cystectomy was lower than the clinical tumor stage, established at the time of transurethral resection of the bladder tumor,” she explains.

Advertisement

Their analysis included 889 patients, 303 with variant histology and 586 non-variant histology patients, all of whom underwent radical cystectomy from 1980 to 2018. Patients with variant histology were matched with pure urothelial carcinoma patients by age, sex, clinical tumor and nodal stages, year of radical cystectomy and receipt of the neoadjuvant chemotherapy.

“Our primary finding is that patients with variant histology can respond to neoadjuvant chemotherapy, demonstrated by pathologic downstaging,” Dr. Campbell says.

“Patients with pure urothelial carcinoma showed pathologic downstaging, which reinforces the role of neoadjuvant chemotherapy in their clinical management, and the matched variant histology cohort had strikingly similar rates.”

The rates of downstaging across variant histology subgroups varied, which should be considered, but Byron Lee, MD, PhD, senior author of the study and urologic oncologist in the Glickman Institute, says these findings provide a basis for broader inclusion of neoadjuvant therapy for this patient population going forward.

“This could mean potentially improving outcomes for select patients,” he says. “It answers some unknown questions in the management of these patients and opens the door for broader, multi-institutional collaborations to better understand this rare and comparatively aggressive pathology.”

Advertisement

Related Articles

Cancer researchers
December 5, 2024/Cancer/News & Insight
Study Examines Neoantigen Landscapes and Their Role in Immunotherapy Efficacy

Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance

Interactive culinary medicine class
November 11, 2024/Cancer/Innovations
Integrative Oncology Improves Outcomes and Quality of Life

Combining mind, body and lifestyle practices in alignment with conventional cancer treatment

Pregnant woman
November 6, 2024/Cancer/News & Insight
Large Retrospective Study Finds Pregnancy Safe Among Young BRCA Carriers

Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Hurthle cell carcinoma
October 24, 2024/Cancer/News & Insight
Researchers Uncover Clues to Treating Rare Thyroid Cancer

Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Ad